Table of contents :
|
|
|
|
n |
|
|
|
|
|
|
||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
||
| Vigoritoref | 37 | 16 | 18 | 12 | 17 | 78 | 63 | 27 | 19 | 100 | 50 | 47 | 51 |
| Blaiseref | 101 | 15 | 21 | 13 | 21 | 23 | 21 | 44 | 42 | 50 | 28 | 61 | 61 |
| Powlesref | 39 | 17.5 | 23 | 11 | 18 | 31 | 35 | 68 | 58 | 44 | 40 | 70 | 68 |
| Heldalref | 61 | 17 | 23 | 13 | 21 | 17 | 10 | 21 | 10 | 56 | 27 | 80 | 73 |
| Schmitzref | 350 | 12 | 15 | 15 | 20 | ND | ND | 52 | 39 | 74 | 53 | ND | ND |
| Coubanref | 228 | 19 | 22 | 16 | 22 | 7.5 | 16 | 40 | 40 | 71 | 55 | 68 | 55 |
| Bensingerref | 172 | 16 | 21 | 13 | 19 | 21 | 30 | 64 | 57 | 46 | 35 | 66 | 54 |
|
|
|
|
|
|
| # donors | 96 | 102 | 32 | |
| Total # LP procedures required | 1.26 ± 0.5 | 1.20 ± 0.5 | 1.6 ± 0.7 | G vs G/GM: .5; G vs GM: .002 |
| CD34 (x 106/kg) | 9.8 ± 7.2 | 10.9 ± 7.9 | 3.7 ± 2.0 | G vs G/GM: .28; G vs GM: < .001 |
| CD3 (x 108/kg) | 3.5 ± 2.4 | 1.8 ± 1.5 | 1.8 ± 1.8 | G vs G/GM: < .0001; G vs GM: < .001 |
| CD4 (x 108/kg) | 2.3 ± 1.4 | 1.3 ± 1.0 | 0.9 ± 0.8 | G vs G/GM: < .0001; G vs GM: < .001 |
| CD8 (x 108/kg) | 1.1 ± 0.7 | 0.4 ± 0.4 | 0.3 ± 0.26 | G vs G/GM: .56; G vs GM: .002 |
| CD19 (x 108/kg) | 0.97 ± 0.9 | 0.89 ± 0.63 | 0.45 ± 0.4 | G vs G/GM: .56; G vs GM: .002 |
| CD16/56 (x 107/kg) | 4.63 ± 3.7 | 2.98 ± 2.36 | 1.66 ± 1.18 | G vs G/GM: < .001; G vs GM: < .0001 |
| G-CSF, % n = 40 | G-CSF and GM-CSF, % n = 66 | GM-CSF, % n = 30 | P Value | |
| acute grade 2–4 | 51 | 65 | 13 | G vs GM: .003
GM vs G/GM: < .0001 G vs G/GM: .11 |
| acute grade 3–4 | 11 | 13 | 0 | .07 |
| chronic GVHD | 86 | 88 | 65 | NS |
| survival (2 years) | 62
high 38 low 88 |
56
high 28 low 5 |
59
high 35 low 69 |
NS |